Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
CC transcript
UROLOGIX INC (ULGX) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/12/2016 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
05/17/2016 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
03/25/2016 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
02/23/2016 SC 13D/A PERKINS CAPITAL MANAGEMENT INC reports a 20% stake in Urologix Inc
02/05/2016 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
02/01/2016 SC 13D/A PERKINS CAPITAL MANAGEMENT INC reports a 23.3% stake in Urologix Inc
11/04/2015 SC 13D/A PERKINS CAPITAL MANAGEMENT INC reports a 23.3% stake in Urologix Inc
07/10/2015 8-K Form 8-K - Current report
07/07/2015 SC 13D/A PERKINS CAPITAL MANAGEMENT INC reports a 24.4% stake in Urologix Inc
05/14/2015 10-Q Quarterly Report for the period ended March 31, 2015
05/13/2015 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Recent Quarter Results"
04/02/2015 4 Form 4 - Statement of changes in beneficial ownership of securities
03/23/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Letter Agreement Regarding Offer of Employment by Urologix, Inc. and Scott M. Madson",
"Letter Agreement Regarding Change In Control Benefits between Urologix, Inc. and Scott M. Madson",
"Urologix Announces Hiring of Chief Financial Officer"
02/13/2015 10-Q Quarterly Report for the period ended December 31, 2014
02/06/2015 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Urologix, Inc. Statements of Operations Three Months Ended December 31, Six Months Ended December 31, 2014 2013 2014 2013 Sales $ 3,079 $ 3,806 $ 6,100 $ 7,585 Cost of goods sold 1,615 2,008 3,174 3,923 Gross profit 1,464 1,798 2,926 3,662 Costs and expenses: Sales and marketing 729 1,681 1,539 3,527 General and administrative 467 561 955 1,246 Research and development 337 452 671 874 Change in value of acquisition consideration — — Medical device tax 48 59 96 119 Amortization expense 17 22 40 44 Total costs and expenses 1,598 2,690 3,301 5,717 Operating loss Interest expense Foreign currency exchange gain/ 1 2 Loss before income taxes Income tax expense 4 16 9 28 Net loss $ $ $ $ Net loss per common share--basic $ $ $ $ Net loss per common share--diluted $ $ $ $ Weighted average num..."
01/28/2015 SC 13D/A PERKINS CAPITAL MANAGEMENT INC reports a 25.5% stake in Urologix Inc
01/12/2015 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Docs: "Urologix Reports Preliminary Fiscal Year 2015 Second Quarter Revenue and Cash Results"
01/09/2015 SC 13D/A PERKINS CAPITAL MANAGEMENT INC reports a 25.5% stake in Urologix Inc
12/10/2014 SC 13D/A PERKINS CAPITAL MANAGEMENT INC reports a 27.2% stake in Urologix Inc
11/24/2014 4 EMERY SIDNEY W JR (Director) has filed a Form 4 on UROLOGIX INC
Txns: Sold 10,000 shares @ $0.0854, valued at $854
Sold 10,000 shares @ $0.0854, valued at $854
11/21/2014 4 Spangler Patrick D (Director) has filed a Form 4 on UROLOGIX INC
11/21/2014 4 EMERY SIDNEY W JR (Director) has filed a Form 4 on UROLOGIX INC
Txns: Granted 45,455 shares @ $0
11/21/2014 4 DANN MITCHELL (Director) has filed a Form 4 on UROLOGIX INC
11/21/2014 4 Barys Christopher R (Director) has filed a Form 4 on UROLOGIX INC
11/13/2014 10-Q Quarterly Report for the period ended September 30, 2014
11/10/2014 8-K Submission of Matters to a Vote of Security Holders
11/05/2014 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Urologix, Inc. Statements of Operations"
09/25/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/23/2014 DEF 14A Form DEF 14A - Other definitive proxy statements:
09/19/2014 10-K Annual Report for the period ended June 30, 2014
08/20/2014 8-K Quarterly results
Docs: "Urologix, Inc. Statements of Operations Three Months Ended June 30, Twelve Months Ended June 30, 2014 2013 2014 2013 Sales $ 3,294 $ 4,184 $ 14,235 $ 16,590 Cost of goods sold 1,711 2,279 8,142 8,407 Gross profit 1,583 1,905 6,093 8,183 Costs and expenses: Sales and marketing 1,011 2,080 5,850 7,719 General and administrative 526 421 2,299 2,515 Research and development 344 514 1,625 2,269 Change in value of acquisition consideration — Impairment of goodwill 3,036 — 3,036 — Gain on demutualization — — — Impairment of identifiable intangible assets — 160 — 160 Medical device tax 51 65 223 106 Amortization expense 23 26 95 104 Total costs and expenses 4,991 3,187 13,023 12,105 Operating loss Interest expense Gain on debt extinguishment — 206 — 206 Foreign currency exchange gain/ 2 Loss..."
08/19/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/15/2014 4 Fluet Gregory (CEO) has filed a Form 4 on UROLOGIX INC
08/15/2014 4 Ackermann Lisa A (EVP, Sales and Marketing) has filed a Form 4 on UROLOGIX INC
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy